Tango Therapeutics, Inc. TNGX
We take great care to ensure that the data presented and summarized in this overview for Tango Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TNGX
View all-
Trv Gp Iv, LLC Boston, MA16.9MShares$115 Million97.21% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA10.7MShares$73.2 Million11.21% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA10.6MShares$72.5 Million4.69% of portfolio
-
Farallon Capital Management LLC San Francisco, CA9.16MShares$62.5 Million0.21% of portfolio
-
Woodline Partners LP San Francisco, CA6.03MShares$41.1 Million0.18% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.91MShares$40.3 Million0.05% of portfolio
-
Nextech Invest Ag5.53MShares$37.7 Million3.19% of portfolio
-
Nextech Invest, Ltd. Zurich, V85.53MShares$37.7 Million5.36% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.03MShares$27.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.99MShares$27.2 Million0.0% of portfolio
Latest Institutional Activity in TNGX
Top Purchases
Top Sells
About TNGX
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Insider Transactions at TNGX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 16
2025
|
Third Rock Ventures Iv, L.P. |
SELL
Open market or private sale
|
Direct |
363,541
-2.47%
|
$2,544,787
$7.04 P/Share
|
|
Sep 08
2025
|
Third Rock Ventures Iv, L.P. |
SELL
Open market or private sale
|
Direct |
86,459
-0.58%
|
$605,213
$7.04 P/Share
|
|
Sep 05
2025
|
Third Rock Ventures Iv, L.P. |
SELL
Open market or private sale
|
Direct |
642,906
-4.16%
|
$4,500,342
$7.0 P/Share
|
|
Aug 22
2025
|
Third Rock Ventures Iv, L.P. |
SELL
Open market or private sale
|
Direct |
302,194
-1.92%
|
$2,115,358
$7.0 P/Share
|
|
Aug 19
2025
|
Third Rock Ventures Iv, L.P. |
SELL
Open market or private sale
|
Direct |
1,100,000
-6.52%
|
$7,700,000
$7.01 P/Share
|
|
Jun 05
2025
|
Lesley Ann Calhoun |
BUY
Grant, award, or other acquisition
|
Direct |
6,250
+33.33%
|
-
|
|
Jun 05
2025
|
Malte Peters |
BUY
Grant, award, or other acquisition
|
Direct |
6,250
+26.32%
|
-
|
|
Jun 05
2025
|
Alexis Borisy |
BUY
Grant, award, or other acquisition
|
Direct |
6,250
+26.32%
|
-
|
|
Jun 05
2025
|
John B Ketchum |
BUY
Grant, award, or other acquisition
|
Direct |
6,250
+22.99%
|
-
|
|
Jun 05
2025
|
Mace Rothenberg |
BUY
Grant, award, or other acquisition
|
Direct |
6,250
+14.29%
|
-
|
|
Feb 05
2025
|
Douglas Barry General Counsel |
SELL
Open market or private sale
|
Direct |
2,556
-3.73%
|
$7,668
$3.16 P/Share
|
|
Feb 05
2025
|
Daniella Beckman Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,948
-2.56%
|
$11,844
$3.16 P/Share
|
|
Feb 05
2025
|
Adam Crystal |
SELL
Open market or private sale
|
Direct |
6,851
-4.15%
|
$20,553
$3.16 P/Share
|
|
Feb 05
2025
|
Barbara Weber Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
9,013
-0.55%
|
$27,039
$3.16 P/Share
|
|
Feb 04
2025
|
Douglas Barry General Counsel |
SELL
Open market or private sale
|
Direct |
2,774
-3.89%
|
$5,548
$2.99 P/Share
|
|
Feb 04
2025
|
Daniella Beckman Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,284
-2.7%
|
$8,568
$2.99 P/Share
|
|
Feb 04
2025
|
Adam Crystal |
SELL
Open market or private sale
|
Direct |
7,432
-4.31%
|
$14,864
$2.99 P/Share
|
|
Feb 04
2025
|
Barbara Weber Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
9,778
-0.6%
|
$19,556
$2.99 P/Share
|
|
Feb 03
2025
|
Daniella Beckman Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,119
+14.15%
|
-
|
|
Feb 03
2025
|
Douglas Barry General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
27,363
+27.72%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 244K shares |
|---|---|
| Open market or private purchase | 20K shares |
| Open market or private sale | 9.83M shares |
|---|